Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week High at $44.38

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) hit a new 52-week high on Tuesday . The stock traded as high as $44.38 and last traded at $43.42, with a volume of 209762 shares. The stock had previously closed at $43.19.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on DYN. HC Wainwright increased their target price on Dyne Therapeutics from $36.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, May 20th. Oppenheimer reissued an “outperform” rating and issued a $47.00 target price on shares of Dyne Therapeutics in a research note on Monday, May 6th. JPMorgan Chase & Co. increased their target price on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 9th. Chardan Capital increased their target price on Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, May 21st. Finally, Morgan Stanley initiated coverage on Dyne Therapeutics in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $43.11.

Dyne Therapeutics Price Performance

The company has a market capitalization of $3.73 billion, a PE ratio of -10.76 and a beta of 1.07. The firm has a 50-day moving average of $35.16 and a 200 day moving average of $27.98.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Thursday, May 2nd. The company reported ($0.81) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.81). Equities analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, COO Susanna Gatti High sold 10,163 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $35.33, for a total value of $359,058.79. Following the transaction, the chief operating officer now owns 148,792 shares of the company’s stock, valued at $5,256,821.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, COO Susanna Gatti High sold 10,163 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $35.33, for a total value of $359,058.79. Following the transaction, the chief operating officer now owns 148,792 shares of the company’s stock, valued at $5,256,821.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Richard William Scalzo sold 2,588 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $28.27, for a total value of $73,162.76. Following the sale, the senior vice president now owns 116,695 shares of the company’s stock, valued at approximately $3,298,967.65. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 202,133 shares of company stock valued at $6,500,387. 20.77% of the stock is owned by company insiders.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of DYN. Nisa Investment Advisors LLC boosted its holdings in Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after acquiring an additional 669 shares during the period. Wetzel Investment Advisors Inc. purchased a new position in Dyne Therapeutics during the 1st quarter valued at $28,000. China Universal Asset Management Co. Ltd. boosted its holdings in Dyne Therapeutics by 355.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock valued at $94,000 after acquiring an additional 5,541 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in Dyne Therapeutics by 28.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after acquiring an additional 1,291 shares during the period. Finally, SG Americas Securities LLC purchased a new position in Dyne Therapeutics during the 4th quarter valued at $172,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.